Artículos del autor

solaci

STRUCTURAL HEART DISEASE

Virtual ACC 2020 | PARTNER 3: TAVR vs CABG in Low Risk at 2 Years

The 2-year outcomes in patients with severe aortic stenosis and low surgical risk continue to show a...
solaci -
Antithrombotic Anticoagulants

Virtual ACC 2020 | Antidote for Life-Threatening Bleeding with New Anticoagulant Agents

Among patients hospitalized with life-threatening or uncontrolled bleeding under treatment with direct factor Xa inhibition, anticoagulation reversal with...
solaci -
Chronic Ischemic cardiopathy

Virtual ACC 2020 | ISCHEMIA: Quality of Life, Not a Soft Endpoint

In the general study, an invasive strategy followed by revascularization (when necessary) vs. an initially conservative strategy...
solaci -
Chronic Ischemic cardiopathy

Virtual ACC 2020 | Relationship between Ischemia Severity and CAD

The ISCHEMIA trial enables countless sub-studies. Many of them have made part of the virtual ACC 2020,...
solaci -
Chronic Ischemic cardiopathy

Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM

In November 2019, during the American Heart Association (AHA) 2019 Scientific Sessions, researchers presented this revolutionary trial...
solaci -
Acute coronary syndromes

Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness

Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to...
solaci -
Antiplatelet

Virtual ACC 2020 | TAILOR-PCI: Gene-Based Prescribing of Clopidogrel Does Not Change Outcomes

This very interesting work leaves us with a sour taste in our mouth, as it failed to...
solaci -
Other

Virtual ACC 2020 | Vericiguat: New Hope in Chronic Cardiac Failure

Treatment with the new drug called Vericiguat (acting on guanosine monophosphate receptors GMP) might reduce cardiovascular mortality...
solaci -